Over a month ago
Recommendations
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Celldex with a $55 price target as part of her "New Year's Countdown" of 10 stocks with 2023 catalysts that should be on investors' radar. Celldex's barzolvolimab has been one of the most followed clinical candidates in the space, and 2023 should bring updates across multiple indications, potentially starting in February, Kluska tells investors in a research note. She believes investors see opportunity for barzolvolimab beyond chronic spontaneous urticaria and chronic inducible urticaria.
Show Hide Related Items >> <<
12/06/22 Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Guggenheim Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 12/23/22 Sell these stocks now, proven algorithm says 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
On The Fly
Show Hide Related Items >> <<
12/13/22 Cathie Wood's ARK Investment bought 49K shares of Verve Therapeutics today 12/12/22 Cathie Wood's ARK Investment bought 58K shares of Verve Therapeutics today 12/07/22 Cathie Wood's ARK Investment bought 106K shares of Verve Therapeutics today 12/06/22 Cathie Wood's ARK Investment bought 330.4K shares of Verve Therapeutics today 11/22/22 Toast director Bennett sells 132,709 class A shares 11/11/22 Toast Inc trading resumes 11/11/22 Toast Inc trading halted, volatility trading pause 11/10/22 Toast jumps 8% to $21.60 after Q3 results and FY22 guidance raise 12/09/22 Nuscale Power names Karin Feldman interim COO/CNO 12/01/22 Nuscale Power signs collaboration agreement for clean hydrogen research 07/28/22 Nuscale Power signs Business Collaboration Agreement with NTS 07/12/22 Nuscale Power and Paragon Energy sign license agreement for HIPS platform 11/08/22 U.S. video game spending fell 5% y/y in Q3, says NPD 10/31/22 GameStop's NFT marketplace launches with ImmutableX 10/31/22 GameStop rises 11.8% 10/31/22 GameStop trading resumes 12/15/22 Guardant Health reports 'positive' results from ECLIPSE study 12/08/22 Guardant Health announces collaboration with AstraZeneca 08/31/22 Guardant Health expands strategic collaboration with Merck KGaA in oncology 08/12/22 Guardant Health receives FDA approval Guardant360 CDx liquid biopsy test as CDx 12/20/22 Exact Sciences: Medicare updates to improve cancer screening access 12/16/22 Arvinas appoints Everett Cunningham to board of directors 12/09/22 Exact Sciences announces initial clinical validation data for POLAR 11/02/22 Cathie Wood's ARK Investment bought 106.8K shares of Exact Sciences today 12/06/22 Equinox Gold sells Solaris Resources shares for C$70.4M 10/19/22 Equinox Gold announces results of Feasibility Study to expand Los Filos Mine 10/13/22 Sandstorm Gold provides update on royalty portfolio 10/04/22 Equinox Gold reports commercial production at Santa Luz Gold Mine 12/06/22 Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 12/21/22 Carnival sees FY23 CapEx $3.4B 12/21/22 Carnival sees Q1 capacity growth 3.7% compared to 2019 12/21/22 Carnival sees FY23 total capacity growth of 3% compared to 2019 12/21/22 Carnival: FY23 advanced booked position higher than historical average 12/15/22 Goldman Sachs Verve Therapeutics initiated with a Sell at Goldman Sachs 12/05/22 Stifel Verve FDA request 'provides fodder for both bulls and bears,' says Stifel 12/02/22 Guggenheim Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim 10/06/22 Credit Suisse Verve Therapeutics initiated with a Neutral at Credit Suisse 12/07/22 National Bank Equinox Gold price target raised to C$5.50 from C$5 at National Bank 12/07/22 BMO Capital Equinox Gold price target raised to C$6.50 from C$6 at BMO Capital 11/07/22 BMO Capital Equinox Gold price target lowered to C$6 from C$7.50 at BMO Capital 11/04/22 National Bank Equinox Gold price target lowered to C$4 from C$5 at National Bank 12/16/22 Goldman Sachs Goldman says Guardant selloff, Exact Science rally an overreaction 12/16/22 BofA Guardant Health price target raised to $70 from $65 at BofA 12/16/22 Cowen Guardant Health price target lowered to $70 from $83 at Cowen 12/16/22 Morgan Stanley Guardant's 'optical miss' presents 'compelling' entry point, says Morgan Stanley 12/16/22 Wells Fargo Wells Fargo sees significant opportunity ahead for Toast 12/12/22 Mizuho Fiserv price target lowered to $135 from $145 at Mizuho 11/29/22 Wolfe Research Toast initiated with a Peer Perform at Wolfe Research 11/11/22 Needham Toast price target raised to $32 from $27 at Needham 12/21/22 Stifel Carnival's lack of full-year guidance shouldn't be concerning, says Stifel 12/15/22 Barclays Carnival price target raised to $12 from $10 at Barclays 12/14/22 Stifel Carnival price target raised to $18 at Stifel, would buy ahead of Q4 report 12/12/22 Credit Suisse Credit Suisse keeps Outperform on Carnival, lowers price target to $19 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Guggenheim Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/29/22 RBC Capital GDS Holdings price target lowered to $15 from $22 at RBC Capital 11/23/22 Truist GDS Holdings price target lowered to $50 from $75 at Truist 11/23/22 HSBC GDS Holdings price target lowered to $36 from $39 at HSBC 08/26/22 RBC Capital GDS Holdings downgraded to Sector Perform from Outperform at RBC Capital 12/08/22 Wedbush GameStop price target lowered to $5.30 from $6 at Wedbush 10/13/22 Jefferies GameStop transferred with a Hold at Jefferies 08/16/22 B. Riley B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell 07/22/22 Wedbush GameStop price target lowered to $7.50 from $30 at Wedbush 10/25/22 UBS Nuscale Power initiated with a Neutral at UBS 08/25/22 Wells Fargo Nuscale Power initiated with an Equal Weight at Wells Fargo 08/18/22 Guggenheim Guggenheim starts 'unique opportunity' Nuscale Power with Buy, $18 target 08/18/22 Guggenheim Nuscale Power initiated with a Buy at Guggenheim 12/16/22 Jefferies Guardant data missing expectations removes overhang on Exact, says Jefferies 11/14/22 Piper Sandler Exact Sciences price target raised to $50 from $40 at Piper Sandler 11/07/22 Raymond James Exact Sciences price target lowered to $60 from $70 at Raymond James 11/07/22 Verve Therapeutics reports Q3 EPS (79c), consensus (74c) 08/09/22 Verve Therapeutics reports Q2 EPS (84c), consensus (63c) 11/10/22 Toast raises FY22 revenue view to $2.692B-$2.722B from $2.62B-$2.66B 11/10/22 Toast sees Q4 revenue $730M-$760M, consensus $731.31M 11/10/22 Toast reports Q3 EPS (19c), consensus (9c) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 12/07/22 GameStop reports Q3 EPS (31c), consensus (28c) 09/07/22 GameStop reports Q2 EPS (36c), consensus (38c) 11/03/22 Guardant Health cuts FY22 revenue view to $440M-$460M, consensus $461.29M 11/03/22 Guardant Health reports Q3 adjusted EPS ($1.18), consensus ($1.26) 08/04/22 Guardant Health backs FY22 revenue $460M-$470M, consensus $465.29M 08/04/22 Guardant Health reports Q2 adjusted EPS ($1.00), consensus ($1.21) 11/21/22 GDS Holdings reports Q3 EPS (3c), consensus (30c) 08/23/22 GDS Holdings sees 2022 revenue RMB 9.25B - RMB 9.4B 08/23/22 GDS Holdings reports Q2 EPS (32c), consensus (30c) 11/03/22 Exact Sciences raises FY22 revenue view to $2.025B-$2.042B, consensus $2.01B 11/03/22 Exact Sciences reports Q3 EPS (84c), consensus ($1.08) 08/02/22 Exact Sciences lowers FY22 revenue view to $1.980B-$2.022B from $1.985B-$2.032B 08/02/22 Exact Sciences reports Q2 EPS (94c), consensus ($1.07) 08/03/22 Equinox Gold reports Q2 EPS (26c) vs. $1.19 last year 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 12/21/22 Carnival sees Q1 adjusted net loss ($850M)-($750M) 12/21/22 Carnival sees Q1 adjusted EBITDA $250M-$350M 12/21/22 Carnival reports Q4 adjusted EPS (85c), consensus (87c) 12/20/22 Notable companies reporting before tomorrow's open
Downgrade
LifeSci Capital analyst…
LifeSci Capital analyst Sam Slutsky downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed his prior price target after the company announced that it is discontinuing the Phase Ib chronic inducible urticaria study with THB001 following the observation of asymptomatic liver transaminitis in two patients. As a result of the "disappointing and unexpected" update, the competitive landscape for chronic urticaria has "become thinner," said Slutsky, who noted that both Celldex (CLDX) and Allakos (ALLK) traded up yesterday following the news.
Show Hide Related Items >> <<
12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 12/06/22 Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 11/29/22 Allakos announces publication of AK006 mechanism of action manuscript 11/10/22 Allakos presents preclinical data on AK007 11/01/22 Codexis appoints Fitzgerald as CLO, General Counsel 09/12/22 Allakos announces initiation of Phase 2b trial of subcutaneous lirentelimab 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley 12/15/22 Guggenheim Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 09/12/22 Cantor Fitzgerald Allakos price target lowered to $7 from $10 at Cantor Fitzgerald 09/12/22 SMBC Nikko Allakos downgraded to Underperform from Neutral at SMBC Nikko 08/08/22 BofA Allakos price target lowered to $4 from $5 at BofA 05/11/22 Barclays Allakos price target lowered to $2.50 from $7 at Barclays 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 08/04/22 Allakos reports Q2 EPS (90c), consensus (85c)
Recommendations
After Third Harmonic Bio…
After Third Harmonic Bio (THRD) announced that the company has decided to discontinue the ongoing Phase 1b study of its investigational drug candidate THB001 after observing asymptomatic liver transaminitis in two trial subjects, Guggenheim analyst Yatin Suneja said the news "puts them even further behind" competitor Celldex (CLDX), which has treated more than 120 patients to date with barzolvolimab with no reported cases of transaminitis. Suneja, who continues to like barzo's profile in chronic urticarias and sees Celldex as "the clear leader in the c-KIT space" with one less competitor, keeps a Buy rating on Celldex shares.
Show Hide Related Items >> <<
12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 12/06/22 Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 10/10/22 Morgan Stanley Morgan Stanley starts Third Harmonic Bio at Overweight on potential of THB001 10/10/22 Cowen Cowen starts Third Harmonic at Outperform on blockbuster potential 10/10/22 Cowen Third Harmonic Bio initiated with an Outperform at Cowen 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year
Conference/Events
Conference call to…
Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
12/06/22 Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
Hot Stocks
Celldex announced new…
Celldex announced new data from the company's open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GALEN Global Urticaria Forum in Berlin. All 9 of 9 - 100% - cold urticaria patients who received a 1.5 mg/kg single full dose of barzolvolimab experienced a complete response as assessed by provocation testing, including 4 of 4 patients with omalizumab refractory disease. This cohort was added to the Phase 1b trial in patients with chronic inducible urticaria after Celldex previously reported a 95% complete response rate in July 2021 in patients with antihistamine-refractory cold urticaria and symptomatic dermographism who received a single 3.0 mg/kg dose of barzolvolimab. The company also added an optional long term follow up evaluation for the initial cohorts of patients treated at 3.0 mg/kg beyond the original 12 week follow up period out to 36 weeks and confirmed that barzolvolimab-induced response and mast cell suppression are durable and linked. A randomized, double-blind, placebo-controlled, multi-dose Phase 2 subcutaneous study of barzolvolimab is currently enrolling patients with both cold urticaria and symptomatic dermographism.
Show Hide Related Items >> <<
11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
Conference/Events
Conference call to…
Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
Conference/Events
Conference call to…
Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link
Show Hide Related Items >> <<
11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
On The Fly
Show Hide Related Items >> <<
11/09/22 Zentalis expects cash to fund requirements into 1Q25 11/08/22 Zai Lab appoints Huang as Chief Scientific Officer 10/24/22 Zentalis announces first ZN-c3 clinical development collaboration with Pfizer 10/17/22 Zentalis appoints Lackner as Chief Translational Officer 11/01/22 Macau reports October casino revenue down 10.7% to 3.9B patacas 10/31/22 Wynn Resorts higher after Fertitta takes 6.1% passive stake 10/27/22 Nevada reports September statewide gaming win up 7.87% to $1.25B 10/18/22 New Jersey reports September gaming revenue up 6.9% to $485M 11/10/22 Warby Parker rises 21.2% 09/26/22 Warby Parker rises 8.7% 08/11/22 Warby Parker rises 19.3% 08/11/22 Warby Parker rises 19.9% 11/02/22 Cathie Wood's ARK Investment bought 156K shares of Unity today 11/01/22 Cathie Wood's ARK Investment bought 332.6K shares of Unity today 10/24/22 Cathie Wood's ARK Investment bought 19.6K shares of Unity today 09/13/22 Unity falls -11.3% 07/28/22 Nuscale Power signs Business Collaboration Agreement with NTS 07/12/22 Nuscale Power and Paragon Energy sign license agreement for HIPS platform 06/22/22 Lightbridge announces Massachusetts MIT awarded $800,000 by DOE 06/20/22 NuScale announces strategic shift to product services and delivery organization 11/03/22 Cassava files lawsuit against perpetrators of 'short and distort' campaign 10/27/22 Cassava Sciences appoints Cook as SVP, general counsel 10/13/22 Cassava Sciences initiates open-label extension simufilam study 10/12/22 Cassava enrolling open-label extension for Phase 3 simufilam trials 11/10/22 Royal Caribbean opens $125M cruise terminal in Galveston with Allure of the Seas 11/03/22 Royal Caribbean sees returning to historical load factors in early summer 2023 11/03/22 Royal Caribbean: Trifecta program to increase adjusted EPS to double digits 11/03/22 Royal Caribbean: FY23 booked well within historical ranges 11/15/22 Paysafe launches paysafecard as alternative payment on Microsoft.com, Xbox.com 10/19/22 Paysafe announces new integrated payments partnership with HotelKey 09/26/22 Paysafe announces entry into Kansas online sports-betting market 09/21/22 Paysafe enters new partnership with Spreedly 11/15/22 Microsoft, Planet to provide AI and satellite data for African climate projects 11/11/22 Planet Labs expands board 10/13/22 Planet Labs announces NASA exercises option to extend contract 09/14/22 Planet Labs teams with Taylor Geospatial for studies on food security, defense PCT PureCycle Technologies 11/09/22 PureCycle Technologies provides Q3 update 08/11/22 PureCycle Technologies provides Q2 operational update 06/30/22 PureCycle CEO Mike Otworth to resign, Dustin Olson promoted to CEO 10/26/22 Oatly Group announces partnership with Aral 09/27/22 Oatly Group debuts YouTube cooking show 'Will it Swap?' 06/16/22 Oatly Group announce results of 2022 Annual General Meeting 06/09/22 Oatly introduces electric heavy duty trucks to fleet in North America 10/17/22 New York Mortgage reports book value per share $3.62-$3.66 at Sept. 30 10/25/22 Monday.com opens latest North American office in Chicago 10/11/22 Monday.com expands global presence with office in Marunouchi, Tokyo 09/20/22 Monday.com opens North American headquarters in NYC 11/14/22 Third Point buys TJX, exits Cenovus Energy in Q3 10/17/22 Archaea Energy rises 53.2% 10/17/22 Archaea Energy rises 52.3% 10/17/22 Archaea Energy rises 52.5% 08/12/22 Soros adds Biohaven, exits Lucid in Q2 07/18/22 Indie Semiconductor opens engineering center of excellence 06/14/22 Indie Semiconductor CEO: We'll cross over the profitability barrier in 2023 06/13/22 Indie Semiconductor set to join Russell 2000 Index on June 27 11/16/22 Inhibrx's chondrosarcoma candidate shows efficacy and safety in Phase 1 trial 10/04/22 Inhibrx announce potential to pursue accelerated approval in U.S. for INBRX-101 08/15/22 Inhibrx: EMA grants orphan drug designation to INBRX-109 06/30/22 Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan 11/08/22 U.S. video game spending fell 5% y/y in Q3, says NPD 10/31/22 GameStop's NFT marketplace launches with ImmutableX 10/31/22 GameStop rises 11.8% 10/31/22 GameStop trading resumes 11/11/22 Freyr Battery announces plan for Georgia Gigafactory 10/27/22 Freyr Battery, ITOCHU partner to develop materials supply chain 10/10/22 Freyr Battery signs license, services agreement with Aleees 09/21/22 Freyr Battery rises 15.9% 11/14/22 3D Systems announces addition of two new materials to its materials portfolio 11/10/22 3D Systems, ALM announce partnership to expand access to 3D printing materials 09/12/22 3D Systems adds chief corporate development officer to Andrew Johnson's title 09/08/22 3D Systems forms new company Systemic Bio, invests $15M 11/11/22 Compass rises 51.0% 11/10/22 Redfin says annual home price growth slows to 3% 11/01/22 New York Attorney General announces agreement with Compass 10/28/22 Compass names Kalani Reelitz as CFO 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 10/25/22 Canopy Growth to acquire Acreage Holdings via Floating Share arrangement 10/25/22 Canopy Growth creates holding company to enter U.S. cannabis market 10/25/22 Constellation Brands to convert common stock holding in Canopy Growth 10/06/22 President Biden says taking steps on marijuana reform 10/03/22 Bilibili announces primary listing on Hong Kong stock exchange 11/03/22 Beam Therapeutics to present ESCAPE approach data at ASH 11/03/22 Beam Therapeutics receives multiple orders from U.S. Marine Corps 09/19/22 Beam Therapeutics presents in vivo data on multiplex base editing approach 08/01/22 Beam Therapeutics drops 12% to $54.99 after FDA places hold on BEAM-201 IND 11/08/22 Affirm CEO: We grew on every metric we care about 11/08/22 Affirm says slowing economy, worsening consumer credit to hamper GMV growth 11/08/22 Affirm reports Q1 Gross Merchandise Volume up 62% y/y at $4.4B 11/08/22 Affirm falls 17% to $12.89 after Q2, FY23 revenue guidance misses estimates 07/20/22 ACV Auctions announces the launch of its Smart Acquisition Manager 10/31/22 Gordon Haskett Gordon Haskett wonders if 'more going on' as Fertitta takes stake in Wynn 10/17/22 Barclays Wynn Resorts price target lowered to $70 from $71 at Barclays 09/26/22 Jefferies Wynn Resorts upgraded to Buy at Jefferies as Macau plans to resume visitation 09/26/22 Jefferies Las Vegas Sands upgraded to Buy at Jefferies as Macau plans to resume visitation 11/16/22 B. Riley Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures 11/16/22 B. Riley Cassava Sciences downgraded to Neutral from Buy at B. Riley 11/08/22 Univest Securities Cassava Sciences price target raised to $12 from $8 at Univest Securities 08/11/22 B. Riley Cassava Sciences price target lowered to $44 from $58 at B. Riley 11/10/22 DA Davidson Affirm price target lowered to $32 from $50 at DA Davidson 11/10/22 Barclays Affirm price target lowered to $16 from $29 at Barclays 11/09/22 Jefferies Affirm price target lowered to $12 from $15 at Jefferies 11/09/22 Truist Affirm price target lowered to $21 from $30 at Truist 10/31/22 Cowen Cowen starts Freyr Battery at Outperform, sees 'less technology risk' 10/31/22 Cowen Freyr Battery initiated with an Outperform at Cowen 09/21/22 Morgan Stanley Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley 09/01/22 BTIG Freyr Battery price target raised to $25 from $20 at BTIG 07/20/22 Deutsche Bank Indie Semiconductor price target lowered to $10 from $11 at Deutsche Bank 06/15/22 B. Riley B. Riley downgrades eight semi stocks on 'demand destruction risk' 06/15/22 B. Riley Indie Semiconductor downgraded to Neutral from Buy at B. Riley 05/13/22 B. Riley Indie Semiconductor price target lowered to $9 from $15 at B. Riley 10/25/22 UBS Nuscale Power initiated with a Neutral at UBS 08/25/22 Wells Fargo Nuscale Power initiated with an Equal Weight at Wells Fargo 08/18/22 Guggenheim Guggenheim starts 'unique opportunity' Nuscale Power with Buy, $18 target 08/18/22 Guggenheim Nuscale Power initiated with a Buy at Guggenheim 08/16/22 Credit Suisse 3D Systems initiated with an Underperform at Credit Suisse 05/11/22 Craig-Hallum 3D Systems price target lowered to $10 from $18 at Craig-Hallum 05/10/22 BofA 3D Systems price target lowered to $12 from $23 at BofA 03/01/22 Craig-Hallum 3D Systems price target lowered to $18 from $33 at Craig-Hallum 08/31/22 Susquehanna Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see' 08/31/22 Susquehanna Paysafe downgraded to Neutral from Positive at Susquehanna 08/11/22 Credit Suisse Paysafe downgraded to Underperform from Neutral at Credit Suisse 08/10/22 RBC Capital Paysafe downgraded to Sector Perform from Outperform at RBC Capital 11/08/22 Credit Suisse Beam Therapeutics price target lowered to $53 from $65 at Credit Suisse 08/10/22 Barclays Beam Therapeutics price target raised to $60 from $38 at Barclays 07/18/22 BMO Capital Beam Therapeutics price target raised to $61 from $41 at BMO Capital 06/16/22 BMO Capital Beam Therapeutics initiated with a Market Perform at BMO Capital 11/14/22 Wells Fargo Archaea Energy downgraded to Equal Weight from Overweight at Wells Fargo 10/04/22 Wells Fargo Archaea Energy initiated with an Overweight at Wells Fargo 06/17/22 Barclays Barclays starts Archaea Energy at Overweight on 'vast' growth potential 06/17/22 Barclays Archaea Energy initiated with an Overweight at Barclays 11/15/22 Credit Suisse Monday.com price target lowered to $140 from $180 at Credit Suisse 11/15/22 Citi Monday.com price target raised to $138 from $135 at Citi 11/15/22 Canaccord Monday.com price target lowered to $120 from $165 at Canaccord 10/21/22 Citi Monday.com price target lowered to $135 from $156 at Citi 11/16/22 RBC Capital Oatly Group price target lowered to $7 from $8 at RBC Capital 11/16/22 Mizuho Oatly Group price target lowered to $2.50 from $3.50 at Mizuho 09/13/22 Credit Suisse Oatly Group downgraded to Neutral from Outperform at Credit Suisse 08/03/22 RBC Capital Oatly Group price target lowered to $9 from $14 at RBC Capital 11/14/22 Wedbush Zentalis price target lowered to $32 from $51 at Wedbush 11/14/22 Wells Fargo Zentalis price target lowered to $46 from $52 at Wells Fargo 11/10/22 Oppenheimer Zentalis price target lowered to $50 from $80 at Oppenheimer 08/10/22 SVB Securities Zentalis price target lowered to $42 from $67 at SVB Securities 10/05/22 Evercore ISI Inhibrx price target raised to $60 from $54 at Evercore ISI 08/09/22 Credit Suisse Inhibrx price target lowered to $48 from $53 at Credit Suisse 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 11/10/22 Citi ACV Auctions price target lowered to $11 from $13 at Citi 11/10/22 Canaccord ACV Auctions price target lowered to $12 from $18 at Canaccord 10/06/22 Jefferies ACV Auctions price target lowered to $15 from $17 at Jefferies 06/30/22 JMP Securities ACV Auctions price target lowered to $10 from $20 at JMP Securities 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright PCT PureCycle Technologies 11/11/22 Cowen PureCycle Technologies price target lowered to $11 from $15 at Cowen 09/15/22 Stifel PureCycle Technologies initiated with a Buy at Stifel 08/15/22 Cowen PureCycle Technologies price target lowered to $15 from $17 at Cowen 03/10/22 Craig-Hallum PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum 11/02/22 BofA Bilibili downgraded to Neutral at BofA on 'challenging' monetization outlook 11/02/22 BofA Bilibili downgraded to Neutral from Buy at BofA 10/28/22 Barclays Bilibili price target lowered to $13 from $21 at Barclays 10/27/22 Citi Bilibili downgraded to Neutral at Citi due to uncertainty over growth, profit 09/01/22 Needham Needham says Compass is 'preferred way' to play difficult real estate market 08/16/22 Barclays Compass price target lowered to $5 from $7 at Barclays 07/21/22 Morgan Stanley Compass downgraded to Equal Weight from Overweight at Morgan Stanley 05/16/22 Oppenheimer Compass price target lowered to $9 from $14 at Oppenheimer 10/25/22 B. Riley New York Mortgage price target lowered to $5 from $5.50 at B. Riley 07/17/22 Barclays New York Mortgage price target lowered to $3 from $3.50 at Barclays 07/17/22 Keefe Bruyette New York Mortgage downgraded to Market Perform at Keefe Bruyette 04/27/22 Barclays New York Mortgage price target lowered to $3.50 from $4 at Barclays 11/17/22 Credit Suisse Norwegian Cruise downgraded to Underperform from Outperform at Credit Suisse 11/14/22 UBS Royal Caribbean price target raised to $76 from $56 at UBS 10/21/22 Tigress Financial Royal Caribbean shares have upside to $80, says Tigress Financial 10/12/22 UBS Royal Caribbean price target lowered to $56 from $65 at UBS 11/17/22 Stifel Unity price target raised to $40 from $30 at Stifel 11/15/22 Goldman Sachs Unity reinstated with a Neutral at Goldman Sachs 11/10/22 DA Davidson Unity price target lowered to $40 from $60 at DA Davidson 11/10/22 Oppenheimer Unity price target lowered to $28 from $60 at Oppenheimer 11/11/22 Baird Warby Parker price target lowered to $23 from $25 at Baird 11/11/22 Citi Warby Parker price target lowered to $26 from $29 at Citi 07/22/22 Piper Sandler Warby Parker initiated with an Overweight at Piper Sandler 07/21/22 Goldman Sachs Warby Parker price target lowered to $12 from $16 at Goldman Sachs 10/13/22 Jefferies GameStop transferred with a Hold at Jefferies 08/16/22 B. Riley B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell 07/22/22 Wedbush GameStop price target lowered to $7.50 from $30 at Wedbush 05/26/22 Wedbush Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns 11/08/22 Deutsche Bank Planet Labs initiated with a Buy at Deutsche Bank 09/13/22 Needham Planet Labs price target raised to $9 from $8 at Needham 06/15/22 Craig-Hallum Planet Labs price target lowered to $10 from $15 at Craig-Hallum 06/15/22 Needham Planet Labs price target lowered to $8.00 from $10.50 at Needham 11/09/22 Bernstein Two more states legalize cannabis, $3B added to TAM, says Bernstein 11/07/22 Canaccord Canopy Growth price target raised to C$5 from C$4.25 at Canaccord 11/01/22 Bernstein Bernstein starts Canopy Growth at Underperform, sees equity raise 11/01/22 Bernstein Canopy Growth initiated with an Underperform at Bernstein 11/09/22 Zentalis reports Q3 EPS (96c), consensus ($1.17) 11/09/22 Wynn Resorts reports Q3 EPS ($1.27), consensus ($1.00) 11/09/22 Notable companies reporting after market close 08/09/22 Wynn Resorts reports Q2 EPS ($1.14), consensus (94c) 08/09/22 Notable companies reporting after market close 11/10/22 Warby Parker raises FY22 revenue view to $590M-$596M from $584M-$595M 11/10/22 Warby Parker reports Q3 adjusted EPS 1c, consensus 1c 08/11/22 Warby Parker lowers 2022 revenue view to $584M-$595M from $650M-$660M 08/11/22 Warby Parker reports Q2 EPS (28c) vs. (35c) a year ago 11/09/22 Unity raises FY22 revenue view to $1.365B-$1.385B from $1.3B-$1.35B 11/09/22 Unity sees Q4 revenue $425M-$445M, consensus $384.82M 11/09/22 Unity reports Q3 adjusted EPS (14c), consensus (15c) 06/03/22 Nuscale Power reports revenue of $2.4M for three month period ended March 31 11/07/22 Cassava Sciences reports Q3 EPS (51c), consensus (48c) 08/03/22 Cassava Sciences reports Q2 EPS (48c), consensus (43c) 11/03/22 Royal Caribbean sees Q4 adjusted EPS ($1.50)-($1.30), consensus (67c) 11/03/22 Royal Caribbean reports Q3 adjusted EPS 26c, consensus 19c 11/02/22 Notable companies reporting before tomorrow's open 11/10/22 Paysafe sees Q4 revenue $370M-$378M, consensus $370.81M 11/10/22 Paysafe raises FY22 revenue view to $1.48B-$1.49B from $1.47B-$1.49B 11/10/22 Paysafe reports Q3 EPS 0c, consensus 0c 09/12/22 Planet Labs sees FY23 revenue $182M-$190M, consensus $182.03M 09/12/22 Planet Labs sees Q3 revenue $45M-$48M, consensus $46.6M 09/12/22 Planet Labs reports Q2 EPS (7c), consensus (16c) 06/14/22 Planet Labs sees FY23 revenue $177M-$187M, consensus $181.26M PCT PureCycle Technologies 08/11/22 PureCycle Technologies reports Q2 EPS (9c), consensus (14c) 11/14/22 Oatly Group sees FY22 revenue $700M-$720M, consensus $798.58M 11/14/22 Oatly Group reports Q3 EPS (18c), consensus (11c) 08/02/22 Oatly Group lowers FY22 revenue view to $800M-$830M from $880M-$920M 08/02/22 Oatly Group reports Q2 EPS (12c), consensus (13c) 11/02/22 New York Mortgage reports Q3 EPS (33c), consensus (4c) 08/02/22 New York Mortgage reports Q2 EPS (22c), consensus 1c 11/14/22 Monday.com reports Q3 EP 5c consensus (54c) 08/08/22 Monday.com sees Q3 revenue $130M-$131M, consensus $125.74M 08/08/22 Monday.com reports Q2 EPS (33c), consensus (75c) 11/10/22 Archaea Energy reports Q3 EPS (18c), consensus 7c 08/16/22 Archaea Energy reports Q2 EPS (18c), consensus 10c 11/10/22 Indie Semiconductor sees Q4 revenue growth to roughly $132M AR run-rate 11/10/22 Indie Semiconductor reports Q3 EPS (31c), consensus (11c) 08/11/22 Indie Semiconductor sees Q3 topline growth 140%-150% 08/11/22 Indie Semiconductor reports Q2 EPS (4c) vs 6c last year 11/07/22 Inhibrx reports Q3 EPS (90c), consensus (94c) 08/08/22 Inhibrx reports Q2 EPS (97c), consensus (78c) 09/07/22 GameStop reports Q2 EPS (36c), consensus (38c) 06/01/22 GameStop reports Q1 EPS ($2.08), consensus ($1.45) 06/01/22 Notable companies reporting after market close 11/14/22 Freyr Battery reports Q3 EPS (80c), consensus (30c) 08/08/22 Freyr Battery reports Q2 EPS 4c, consensus (26c) 11/08/22 3D Systems narrows FY22 revenue view to $535M-$545M from $530M-$570M 11/08/22 3D Systems reports Q3 adjusted EPS (5c), consensus (7c) 08/08/22 3D Systems cuts FY22 revenue view to $530M-$570M from $580M-$625M 08/08/22 3D Systems reports Q2 EPS (7c), consensus 0c 11/10/22 Compass lowers FY22 revenue view to $6.05B-$6.20B from $6.15B-$6.45B 11/10/22 Compass sees Q4 revenue $1.15B-$1.30B, consensus $1.41B 11/10/22 Compass reports Q3 EPS (36c), consensus (34c) 08/15/22 Compass sees FY22 revenue $6.15B-$6.45B, consensus $7.59B 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 11/09/22 Canopy Growth reports Q2 adjusted EBITDA (C$78.1M), up 52% y/y 10/06/22 Constellation Brands reports Q2 comparable EPS ex-Canopy losses $3.33 08/05/22 Canopy Growth reports Q1 EPS (C$5.23) vs. C$0.84 a year ago 06/30/22 Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.90 09/08/22 Bilibili sees Q3 revenue RMB 5.6B - RMB 5.8B 09/08/22 Bilibili reports Q2 adjusted EPS (74c), consensus (64c) 06/09/22 Bilibili sees Q2 revenue RMB4.85B-RMB4.95B from RMB5.05B in Q1 06/09/22 Bilibili reports Q1 adjusted EPS (66c), consensus (62c) 11/07/22 Beam Therapeutics reports Q3 EPS ($1.56), consensus ($1.31) 08/09/22 Beam Therapeutics reports Q2 EPS ($1.02), consensus ($1.08) 11/08/22 Affirm sees FY23 revenue $1.60B-$1.68B, consensus $1.71B 11/08/22 Affirm sees Q2 revenue $400M-$420M, consensus $433.6M 11/08/22 Affirm reports Q1 EPS (86c), consensus (83c) 11/08/22 Notable companies reporting after market close 11/09/22 ACV Auctions sees FY22 revenue $ $421M-$424M, consensus $428M 11/09/22 ACV Auctions sees Q4 revenue $97M-$100M, consensus $104.83M 11/09/22 ACV Auctions reports Q3 EPS (15c), consensus (17c) 08/10/22 ACV Auctions cuts FY22 revenue view to $427M-$432M from $452M-$460M
Hot Stocks
Show Hide Related Items >> <<
07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year 09/16/22 Sell these stocks now, proven algorithm says 07/12/22 Celldex put volume heavy and directionally bearish
